Ra Medical Systems to Participate in A.G.P.’s Virtual Healthcare Symposium

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE: RMED) , a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that management will participate in A.G.P.’s Virtual Healthcare Symposium. This event, which features one-on-one meetings, is being held Thursday, November 19, 2020.

Ra Medical management will be available for one-on-one meetings. Interested investors should contact Ra Medical President Jeffrey Kraws at jkraws@ramed.com or Jody Cain at jcain@lhai.com.

About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017 the DABRA excimer laser system received FDA 510(k) clearance in the U.S. for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. The Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in controlled environments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201113005006/en/